SCHEMBL6024980

SCHEMBL6024980

CCCCC[C@H](CN(O)C=O)C(=O)NNC(=O)c1ccc(-n2ccnc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 7/20 0.45
TDP1 Q9NUW8 1/20 0.41
HTT P42858 1/20 0.41
CYP3A4 P08684 2/20 0.41
BAZ2B Q9UIF8 1/20 0.41
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MMP12 P39900 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6024986 0.84 BMP1 (0.45) BMP1MMP12
SCHEMBL6024200 0.82 CYP3A4 (0.41) BMP1HTTCYP3A4BAZ2BKMT2A
SCHEMBL6024639 0.81 BMP1 (0.51) BMP1MMP12
SCHEMBL6023832 0.80 BMP1 (0.58) BMP1MMP12
SCHEMBL6024074 0.80 BMP1 (0.49) BMP1MMP12CYP2C9
SCHEMBL6024095 0.80 BMP1 (0.48) BMP1KMT2AMAPTMMP12
SCHEMBL6024429 0.80 HDAC11 (0.51) BMP1TDP1MMP12
SCHEMBL6024091 0.79 BMP1 (0.54) BMP1HTTKMT2AMAPTL3MBTL1
SCHEMBL1595000 0.76 BMP1 (0.38) BMP1CYP3A4MMP12CYP1A2CYP2D6
SCHEMBL1594992 0.76 BMP1 (0.38) BMP1CYP3A4MMP12CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP claimed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US claimed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US claimed
EP-1363873-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2016-04-20 EP disclosed
US-7019003-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-03-28 US disclosed
EP-1363873-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP disclosed
US-20040087585-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2004-05-06 US disclosed
EP-1363873-A2 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2003-11-26 EP disclosed
WO-2002070541-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087585-A1 Peptide deformylase inhibitors PDF, DPEP1, PEPD BMP1 1586/4885TDP1 542/4885HTT 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.